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1INTRODUCTION
In 1950, the Eighth Edition of the Price Textbook of
Medicine, outlining the management of patients with Acute
Myocardial Infarction, stated that “taking cases as a whole, it would
appear that somewhat more than half survive the acute attack.  The first
week is particularly dangerous, especially the first two or three days,
and prognosis must be very guarded at least three months of complete
rest, followed by a period of partial rest is strongly indicated”1
Retrospectively, this cautionary approach may seem exaggerated, but it
must be remembered that until 1912, it was believed that acute
myocardial infarction was uniformly fatal.  It was James Herrick, a
Chicago physician, who first described   survival after infarction in an
article that appeared in the Journal of the American Medical Association
in 1912.2
In subsequent years, as the understanding of the
pathophysiological principles of myocardial infarction began to grow,
treatment came to be based on sounder tenets, and the prognosis
began to improve.  Substantial advances in the treatment of acute
myocardial infarction (MI) have occurred over the past several years as
a result of important observations in basic myocardial research and
through the vital evaluative mechanism of randomized clinical trials.3-12
2A steady decline in the mortality rate from STEMI has been
observed across several population groups since 196013. Several
phases in the management of patients have contributed to the decline in
mortality from STEMI.
The “clinical observation phase” of coronary care consumed
the first half of the 20-th century and focused on a detailed recording of
physical and laboratory findings, whereas treatment consisted of strict
bed rest and sedation Subsequently the “coronary care unit phase”
began in the mid 1960s and was notable for detailed analysis and
vigorous management of cardiac arrhythmias. Killip and Kimball
published their seminal article titled ‘The treatment of Myocardial
Infarction in a Coronary Care Unit -- A Two Year Experience with 250
Patients’ in the Lancet in 1967.  Here they espoused the guidelines for
the setting up of such units, and showed conclusively that intensive
treatment, especially of arrythmias, produced striking improvement in
the mortality. This article also expounded the now famous Killip
classification.14
The “high technology phase” was ushered in by the
introduction of the pulmonary artery balloon flotation catheter, setting
the stage for bedside hemodynamic monitoring and more precise
management of heart failure and cardiogenic shock associated with
STEMI.  A battery of tests, sometimes providing overlapping
information, was developed during the high technology phase. The
3modern “reperfusion era” of coronary care was    introduced by
intracoronary and then intravenous fibrinolysis   increased use of
aspirin, and development of primary percutancous coronary intervention
(PCI).
Several of these options -- which include angioplasty, intra-
coronary stenting, intra-coronary brachytherapy, rotablation techniques,
bypass grafting and transmyocardial laser revascularisation are
potentially life-threatening.  Given this scenario, it becomes
important for the physician to have techniques to identify, with
reasonable accuracy, those patients at highest risk for developing
harmful events, in whom such               aggressive intervention may be
advisable despite the risks. Despite therapeutic advances, recent large-
scale randomized     clinical trials report 6% to 9% early mortality rates
(30 to 35 days), even for patients receiving thrombolytic therapy within 6
hours of symptom onset 15-18
Yet another problem, faced by third-world physicians   in
particular, is that in several hospitals, the coronary care   facilities are
severely limited compared to the number of needy patients. Thus, a
system of prognostication is needed in this scenario to choose between
patients and to identify the   poor-prognosis group that may have
maximum benefit from  intensive care.  Prognostication in Acute
4Myocardial Infarction has evolved over the years.  Today, a distinction is
made between short-term or in-hospital prognosis and long-term
prognosis. Various workers in the field have attempted to shift through
the multitude of factors affecting prognosis.
LIMITATIONS OF CURRENT THERAPY
Despite the gratifying success of medical therapy for STEMI,
several observations indicate that considerable room for improvement
exists. The short-term mortality rate of patients with STEMI who receive
aggressive pharmacological reperfusion therapy as part of a
randomized trial is in the range of 6.5 to 7.0 percent, 19 whereas
observational data bases suggest that the mortality rate in STEMI
patients in the community is 15 to 20 percent. 20 In part, this difference
relates to the selection of patients without serious comorbidities for
clinical trials.
Often, choices among alternative therapies or decisions regarding
the allocation of clinical resources are based on an   assessment of
patient risk.  Careful attention to pivotal factors that increase the risk of
early mortality might illuminate the role of second-tier interventions or
adjunctive pharmacotherapeutics that would further lower the fatality
rate of acute MI.
5To be broadly useful, a risk-assessment algorithm should include
all clinically relevant prognostic indicators and should be derived from a
population that represents the types of patients seen in clinical practice
so that stable estimates of true risk    relations can be assessed. A
useful model should appropriately weight clinically relevant predictors
and be validated in a   population with a broad spectrum of patients and
hospital settings, in which risk profiles may soon be required. Though
many studies have attempted to define the prognosis of patients with MI
and/or provide risk algorithms, 21-29 they were performed before the
widespread use of thrombolytic agents 15- 19 or were limited in sample
size, diversity of medical care systems, or spectrum of  clinical data.
In this study, an attempt has been made to apply
prognostic factors cited in the literature in the setting of a teaching
hospital situated in predominantly rural surroundings.  Our institution
regularly faces a demand for intensive cardiac care well out of
proportion to the available facilities -- hence such a study is especially
significant in our context.  Only those described factors that are easily
available in such a setting have been selected for the purposes of the
study.  The attempt has been to identify the factors that will help the
attending physician to reasonably identify those patients at highest risk
of short-term mortality so that the relatively scarce resources can be
allotted in the most efficient and beneficial manners possible.
6AIMS OF THE STUDY
1. To determine the prevalence and prognostic
implications of hyponatremia in the setting of acute ST-elevation
myocardial infarction.
2. To validate the accuracy of frequently used prognostic
index killip classification.
3. To investigate the relative importance of other
prognostic factors cited in the literature.
4. To calculate the statistical associations between such
characteristics and short-term prognosis.
7REVIEW   OF  LITERATURE
REVISED DEFINITION OF MYOCARDIAL INFARCTION(MI) 30
Criteria for acute, evolving, or recent MI
Either one of the following criteria satisfies the diagnosis for an
acute, evolving, or recent MI :-
1. Typical rise and gradual fall (troponin) or more rapid rise
and fall (CK-MB) of biochemical markers of myocardial necrosis with at
least one of the following:
a. Ischemic symptoms
b. Development of pathologic Q waves on the ECG reading
c. ECG changes indicative of ischemia (ST-segment
elevation or depression).
d. Coronary artery intervention (e.g., coronary angioplasty)
2. Pathological findings of an acute MI
Criteria for established MI
Either of the following criteria satisfies the diagnosis for
established MI :
81. Development of new pathological Q waves on serial ECG
readings.  The patient may or may not remember previous symptoms.
Biochemical markers of myocardial necrosis may have normalized,
depending on the length of time that has passed since the infarct
developed.
2. Pathological findings of a healed or healing MI.
Several researchers all over the world have been    attempting for
decades to establish those criteria that best define patients with a
poorer prognosis.  Taken in toto, the various studies and articles
published in the literature may be classified conveniently into two major
headings:-
1. Criteria obtained at the initial physician contact --
including patient characteristics (e.g., age, gender), details of
history, the initial clinical examination findings.
2. The laboratory parameters obtained on admission.
CHEST PAIN
Despite the recent advances in the laboratory   diagnosis of Acute
Myocardial Infarction (AMI), the history remains of substantial value in
arriving at a diagnosis.  A   prodrome of chest discomfort can usually be
elicited in 20 to 60% of patients with AMI.31
9The pain of AMI resembles that of classic angina  pectoris, except
that it is more severe, occurs at rest or with lesser activity than usual,
lasts longer (more than 30 minutes), is associated with more systemic
symptoms (e.g., diaphoresis, nausea), and is not relieved by rest or
nitrates.
The essence in the management of AMI today is ‘speed’.
Patients who are hospitalised and treated earlier (especially with
thrombolysis) have a better prognosis.  Hence, all factors that lead to a
delay in diagnosis and treatment, especially the absence of chest pain
or atypical presentations entail a poor prognosis.
In an analysis of the atypical presentations of AMI, Bean et. al.,
lists the following :- 32
1. Congestive heart failure
2. Classic angina pectoris (not severe or prolonged)
3. Atypical locations of the pain
4. Central nervous system manifestations, resulting from
a reduced cardiac output, resembling a stroke.
5. Apprehension and nervousness
6. Sudden mania and psychosis
7. Syncope
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8. Overwhelming weakness
9. Acute indigestion, and
10. Peripheral embolism.
To this list must be added those patients with “silent” AMI -- who
have had no symptoms at onset.  Such presentations are commoner
in diabetics and hypertensives, and both of these conditions are also
associated with an increased mortality.33
TIME SINCE ONSET OF SYMPTOMS
Studies involving large numbers of patients  have revealed
wide variations in the time elapsed between   symptom onset and arrival
at the hospital.  Researchers have  investigated for a relationship
between this delay and inhospital mortality.  However, there are certain
complexities in this   relationship, as follows :-
Most sudden deaths in AMI occur due to ventricular arrythmias,
and this risk is maximum in the first hour after  symptom onset.34 With
each subsequent hour, the risk decreases, giving rise to the paradoxical
situation where a patient who   presents late to the hospital has a lesser
risk of sudden death than one who presents early for treatment.
40 to 60% of patients have some degree of left ventricular (LV)
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dysfunction at presentation , if untreated, this may go on to cardiogenic
shock, the commonest cause of in-hospital death in AMI.35 This implies
that the patient who presents sufficiently early for shock to be treated or
prevented has a better prognosis.
Established beyond reasonable doubt that the patient
who presents early enough for thrombolysis has large  benefits from
reperfusion, vastly improving the prognosis.36
THE CONCEPT OF “DOOR-TO-NEEDLE” TIME
The term door-to-needle time was coinned to figuratively
describe the time elapsed between the patient’s symptom onset upto
the actual intravenous infusion of the thrombolytic agent.  This includes
all the delays involved in contacting a doctor, referral to an ICCU,
obtaining transport, and the time spent in the emergency room or
casualty of the hospital before reaching the ICCU.
Raitt et. al., have shown that each 30 minute delay
is associated with a 1% increase in infarct size.37 Julian D.G., analysing
the results of five mortality trials, concluded that gaining about one hour
prior to thrombolysis decreases mortality by about 17%.38 Even for
patients presenting later than this ‘window’  period of 6 hours,
thrombolysis can be beneficial, compared to those that do not receive
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such treatment.  Yusuf et. al., showed a 22% reduction in  mortality for
those treated at 12 -- 24 hours.  The   ISIS-2 trial extended the concept
of beneficial late perfusion with its results revealing a significant benefit
beyond 6 - 12 hours, and even 12 - 24 hours.36 These findings are
confirmed by the  ISIS-3 and EMERAS trials. The newer agents such
as  t-PA, Urokinase, or even emergency coronary angioplasty may
achieve better late reperfusion than streptokinase.39
AGE OF THE PATIENT
It has long been appreciated that the mortality in AMI is
increased in those over 60 years of age49. Several studies have
documented a greater incidence of congestive failure, malignant
arrythmias and sudden death in this group .  Although the survival of
elderly patients (>65 years of age) after STEMI has improved
significantly, advanced age consistently emerges as one of the principal
determinants of mortality in patients with STEMI.40
The effects of aging on the heart have been well
studied.31 The aging heart has a poorer ability to respond to the
ischemic insult, especially since the remaining perfused areas have a
diminished functional reserve.  Co-existent diseases, prior myocardial
damage and larger infarcts are all commoner in the elderly.31
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Since age has been considered a relative  contraindication, the
benefits of thrombolytic therapy have not been as dramatic in the lderly.
In addition, older patients are more likely to present later (increased
collaterals or autonomic neuropathy), or have other contraindications to
thrombolysis.40
GENDER -- RELATED DIFFERENCES IN PROGNOSIS
Unlike in previous years, the incidence of AMI in women
is increasing.  AMI in women has certain peculiarities.  Women   are
mostly older than men at presentation and are more likely to have
atypical pain.  Hypertension, diabetes, unstable angina, hyperlipidemia,
congestive cardiac failure or silent infarctions are all commoner in
women.  Women more frequently have non-Q AMI and tend to present
later to hospital.41 Of interest, after STEMI, younger women but not
older women have higher rates of   in-hospital mortality than men of the
same age.41
The more serious presentations -- rales, hypotension, heart block
or tachycardia are commoner in women.  It has been noted that
diabetes dramatically increases the mortality among    women > 65.41
The pathogenic mechanisms different in women include : 42
- a greater incidence of vasospastic and microcirculatory
angina,
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- different plaque components (more cellular and fibrous
tissue)
- different endothelial tone due to hormonal influences
- different hemostasis (higher fibrinogen and factor VIII
levels.)
PREVIOUS HISTORY OF CORONARY HEART DISEASE
A preceding history of coronary artery disease can have  varying
effects on the short-term prognosis.33 Patients with a second infarction
are more likely to die than those who suffer at first. This finding,
confirmed in most studies, probably reflects the importance of the extent
of viability of remaining myocardium versus infarcted myocardium in
determining the prognosis.  In all age groups and in both sexes, history
of heart failure is associated with a poorer outcome, with an increased
mortality of 10 to 15% as the NYHA functional class increased from I to
IV.43
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DIABETES AND ITS EFFECT ON PROGNOSIS
Diabetes Mellitus is an important risk factor for the
development of coronary heart disease. The early pioneering
studies on AMI, especially those by Killip and Norris suggested that the
presence of diabetes had a significant effect on the  mortality.  The
famous Framingham Heart Study indicated that  diabetes increased the
risk of death in women, but not men, after  a first AMI.14 They tend to
have larger infarcts, and show  a greater incidence of shock, cardiac
failure and metabolic   problems.44
Hyperglycemia and impaired glucose tolerance are
common in patients with STEMI.  Although the absolute levels  of blood
insulin are often in the normal range, they are usually inappropriately
low for the level of blood sugar, and there may be relative insulin
resistance as well.  Patients with cardiogenic shock often   demonstrate
marked hyperglycemia and depressed levels of circulating insulin, often
with complete suppression of insulin secretion in response to
tolbutamide.  These abnormalities in  insulin secretion and the resultant
impaired glucose tolerance appear to be secondary to a reduction in
pancreatic blood flow   as a consequence of splanchnic vasoconstriction
accompanying  severe left ventricular failure.  In addition, increased
activity of the sympathetic nervous system with augmented circulating
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catecholamines inhibits insulin secretion and augments  glycogenolysis,
also contributing to the elevation of blood sugar.45
Glucose appears to be a more favourable energy source than
free fatty acids for the ischemic myocardium by more   efficiently
replenishing the Krebs cycle and stimulating contractile   performance.46
Because hypoxic heart muscle derives a  considerable portion of its
energy from the metabolism of glucose and because insulin is essential
for the uptake of glucose by the myocardium as well as for myocardial
protein synthesis and inhibition of lysosomal activity, the deleterious
effects of insulin deficiency are clear.  These metabolic considerations,
combined with epidemiological observations that diabetic patients have
a markedly worse prognosis, have served as the foundation for  efforts
to more aggressively administer insulin-glucose infusions to diabetic
patients with STEMI.
To compound matters further, the increased adrenergic
discharge at the time of AMI worsens insulin  resistance, thus impairing
myocardial glycolysis. The concentration of circulating free fatty acids
rises, and this can predispose to the development of malignant
ventricular arrhythmias.31
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HYPERTENSION AND ITS EFFECT ON PROGNOSIS
The GISSI-2 trial, one of the largest ever series of AMI
patients, (11,483 patients, of which 3306 were hypertensive)
investigated the prognostic value of hypertension in those
receiving thrombolysis.  Their results show a significantly higher
mortality for hypertensives, both in-hospital and at 6 months.  LV failure
and recurrent ischemic events were also more common among
hypertensives.47
PULSE, BLOOD PRESSURE AND HEMODYNAMIC
STATUS AT ADMISSION
Despite the tremendous advances in the management
of AMI, the initial clinical examination remains the basic   foundation
upon which all subsequent steps are planned. It has even been
observed that the initial judgment regarding   prognosis by the admitting
doctor, based on the initial clinical   examination correlates well with the
outcome.48 Based on   the admission pulse rate, several judgments can
be made.  Most commonly, the pulse is initially rapid (100 to 110 /
minute) and regular, slowing considerably when the patient’s  pain and
anxiety are relieved.  Sinus tachycardia lasting for more than
18
24 hours carries a poor prognosis.31 Heart rate at entry displayed a
significant U-shaped relation, with elevated mortality at very low and at
high heart rates 49. Previous studies have identified sinus tachycardia as
a indipendent prognostic factor 50.
The majority of patients with AMI are normotensive, although the
associated tachycardia may reduce the systolic  pressure and narrow
the pulse pressure.  While  previously  normotensive patients may show
a hypertensive response due to sympathetic activity, patients with
hypertension may become normotensive owing to the acute circulatory
disturbances. A strong prognostic relation was also present for systolic
blood pressure, notably in the range below 120 mm Hg.  A similar but
less  significant pattern existed for diastolic blood pressure 49.
The SPRINT study group, reporting in October 1995, found an
increasing mortality with increasing heart rates at admission, from less
than 70 to more than 90 / minute.  At even higher heart rates, the
increasing trend of mortality was confined to those with heart failure.  A
combination of a rate more than 90 with a systolic pressure less than
120 mm of Hg was a powerful predictor of    in-hospital mortality.51
In patients with AMI, heart failure is characterised by either
distolic dysfunction (pulmonary congestion or venous
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hypertension) or both diastolic and systolic (decreased cardiac output
and ejection fraction).  Clinical manifestations become more obvious as
the extent of injury increases and thus they carry an adverse prognosis.
These factors have been best quantified by the Killip classification,
which groups patients into four classes with increasing  signs of failure
carrying higher degrees of mortality.14
Patients develop cardiogenic shock when more than 40%
of the myocardium is destroyed.  Beyond the immediate phase,
cardiogenic shock is the commonest cause of mortality.  The
defining characteristics of this condition includes :-
- evidence of hypoperfusion (cold, clammy
skin, impaired mentation, oliguria)
- systolic BP less than 80 to 90 mm of Hg
- LVEDP or PCWP more than 18 mm of Hg.
- cardiac index less than 1.8 mL/min/m2
- evidence of primary cardiac abnormality.
The hospital mortality for cardiogenic shock is in the
region of 60 - 80%.  The incidence of ventricular arrhythmias and heart
block was found to be higher in these patients (Killip et. al.)14 . By
multivariate analysis of their cohort of 845 patients, Hands   et. al.,
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found that the predictors of cardiogenic shock included   age > 65,
ejection fraction < 35% peak CK-MB value more than  160 IU/L., and a
history of diabetes or prior infarction.52
LEUCOCYTE COUNT AND PROGNOSIS
An increase in the white cell count occurs frequently following an
AMI.  This may be a reaction to tissue necrosis, or be the effect of
released catecholamines, or both.  The elevation starts 2 hours after
onset, reaches a peak at 2 to 4 days, and usually ranges from
12-15, 000 per cu.mm., but can occasionally rise upto 20,000.  Often
there is a polymorphonuclear leukocytosis, and a shift tot he left, with
band forms seen 53,54.  The ESR and the PCV may also show transient
rises.
A study by Furman et.al., concluded that the
peripheral blood WBC count correlated directly with short-term
prognosis.  This was independent of other factors such as the site or
size of the infarction.55
Yet another study by Petrov et. al., also found that
a leucocytosis grater than 19,000/cu.mm. was seen in all
patients of AMI in his series who expired in hospital. He   suggests that
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a count greater than 15,000 is an important prognostic sign for the final
outcome of AMI.56
ADMISSION HYPERGLYCEMIA AND PROGNOSIS
Hyperglycemia, inappropriate insulin levels and impaired
glucose tolerance are common in patients with AMI.
Hyperglycemia, even without previous diabetes, is associated with a
high mortality and a higher incidence of failure.57 Patients with
cardiogenic shock often show marked hyperglycemia and low
levels of circulating insulin.58
These abnormalities are in part due to a reduction in
pancreatic blood flow,this is a consequence of intense
splanchnic vasoconstriction which accompanies severe heart
failure. In addition, increased sympathetic activity during AMI
increases catecholamines, inhibits insulin secretion and
augments  glycogenolysis, all leading to hyperglycemia.31
Hypoxic heart muscle derives a considerable portion of
its energy from the metabolism of glucose, and since insulin is
essential for its uptake here, a deficiency of or resistance to insulin has
deleterious effects.
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HYPONATREMIA
Hyponatremia, defined as a plasma sodium level
<135mmol/l (<135mEq/L).  Hyponatremia is a common electrolyte
disorder among hospitalized patients 59, especially in the postoperative
period 60 and in patients with heart failure, nephrotic syndrome, or
cirrhosis 61,62.  It is recognized as a predictor of adverse   outcomes in
hospitalized patients, and its prognostic implications are usually
attributed to the severity of the underlying condition 59,63.  The
prevalence of hyponatremia in hospitalised patients is 2%64.
Hyponatremia can be associated with low, normal, or high tonicity. 65,66
Effective osmolality or tonicity refers to the contribution to
osmolality of solutes, such as sodium and glucose, that cannot move
freely across cell membranes, thereby inducing transcellular shifts in
water.67 Dilutional hyponatremia, by far the most common form of the
disorder, is caused by water retention.  If water intake  exceeds the
capacity of the kidneys to excrete water, dilution of body solutes results,
causing hypo osmolality and hypotonicity (Fig. B, E, F,andG)
Hypotonicity, in turn, can lead to cerebral edema, a potentially life
threatening complication.68 Hypotonic hyponatremia can be associated,
however, with normal or even high serum osmolality if sufficient
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amounts of solutes that can  permeate cell membranes (e.g., urea and
ethanol) have been  retained  (Fig. C).  Importantly, patients who have
hypotonic hyponatremia but normal or high serum osmolality are as
subject to the risks of hypotonicity as are patients with hypo-osmolar
hyponatremia.
The nonhypotonic hyponatremias are hypertonic
(or translocational) hyponatremia and isotonic hyponatremia.65,66
Translocational hyponatremia results from a shift of water from cells to
the extracellular fluid that is driven by solutes confined in the
extracellular compartment (as occurs with hyperglycemia or retention of
hypertonic  mannitol);  serum   osmolality is increased, as is tonicity, the
latter causing dehydration of cells (Fig.D). Retention in the extracellular
space of large volumes of isotonic fluids that do not contain sodium
(e.g., mannitol) generates iso-osmolar and isotonic hypontremia but no
transcellular shifts of water.
A common clinical problem, hyponatremia frequently
develops in hospitalized patients.  Although morbidity varies widely in
severity, serious complications can arise from the disorder itself as well
as from errors in management.
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Suxon LA, found that serum sodium < 134 mEq/liter, is a
independent predictor of hemodynamic deterioration in advanced heart
failure.70
Hyponatremia has been shown to be a predictor of
cardiovascular mortality among patients with heart failure 69,70
MECHANISM OF HYPONATREMIA IN HEART FAILURE
Heart Failure is a complex clinical syndrome that is growing in
maganitude as the population ages.  It is difficult to define but relatively
strightforward to diagnose. Heart failure implice   underlying structural
and functional changes in heart that contribute importantly to the clinical
syndrome.  There is no single cause are unifying mechanism in heart
failure71.
In the presence of heart failure several  mechanism     promote
the development of hyponatremia.  Vasopressin is   essential to the
development of hyponatremia because atleast fifteen liters of fluid can
be excreted daily when Vasopressin is appropriately inhibited 72
25
Hypoosmolarity which inhibits the release of  vasopressin
in healthy subjects is associated with persistently high plasma
concentration of vasopressin in heart failure 69.
The hyponatremia is due in part to nonosmotic release
of AVP, which acts on the kidney to reduce free water clearance.
Release of AVP in heart failure probably occurs via activation of carotid
baroreceptors 73.  Plasma AVP levels are often but not always increased
in patients with  LV dysfunction 74 and heart failure.75 AVP acts on the
V2 receptors in the collecting duct of the kidney via adenylate cyclase to
translocate aquaporin-2 water channels from cytoplasmic vesicles to the
apical surface of the collecting duct.  AVP also increases aquaporin-2
channel synthesis.Activation of V1 receptors in vascular tissue
contributes to heightened vascular resistance and myocardial
dysfunction in heart failure.76
THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
The RAAS plays an important role in the pathogenesis of heart
failure , and consistent benefit has been derived from ACE-inhibitor
therapy in patients with heart failure. The   mechanismsresponsible for
the release of renin from the renal cortex have been exhaustively
studied 77 and include sympathetic drive to the kidneys, hyponatremic
perfusate to the macula densa of the kidney, and use of diuretics and a
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low-sodium diet, which tends to promote a relative volume contraction.
Renin proteolytic enzyme has little biologic activity, but it interacts with
angiotensinogen to split off two amino acids to form angiotensin I, which
is then cleaved by ACE, which is distributed widely in the vascular
system, especially the lungs, to produce angiotensin II,   a peptide with
a vast range of biological activities.   Angiotensin II in turn stimulates
release of aldosterone from the adrenal cortex, which also has an array
of biological effects, including sodium and water retention, kaliuresis,
and enhanced collagen turnover and organ remodeling.
Activation of carotid baroreceptors has been implicated in the
nonosmotic release of vasopressin due to arterial underfilling 61,62,78.  In
addition, increased expression of messenger RNA for vasopressin in
the hypothalamus has been described in animal models 79.  Moreover,
the renal effect of vasopressin is enhanced in heart failure.  The
mechanisms leading to hyponatremia in heart failure may be
responsible in part for the adverse prognosis associated with
hyponatremia.
MECHANISM OF HYPONATREMIA IN ACUTE MI
It is not clear whether the mechanisms that contribute to the
development of chronic hyponatremia are involved in our study.  For
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example, increased hypothalamic expression of vasopressin 79 and
upregulation of water channels in the collecting duct 80 require several
weeks of heart failure to develop.  In the setting of acute myocardial
infarction, hyponatremia on admission or a rapid reduction in plasma
sodium level occurs in a substantial number of patients.  In addition,
hyponatremia remained an    independent predictor of mortality even
after adjustment for the most important clinical and hemodynamic
covariates that determine prognosis in ST-elevation myocardial
infarction 81,82,83.
In acute myocardial infarction, nonosmotic release of
vasopressin may occur due to the acute development of left
ventricular dysfunction, in response to pain, nausea, and major stress,
the most common mechanisms of hyponatremia in adults; or in
response to the administration of analgesics and diuretics 84,85.  In this
setting, vasopressin levels increase concomitantly with the activation of
other neurohormones such as renin and norepinephrine 86.  However,
vasopressin level does not correlate with serum osmolarity in
myocardial infarction 86, suggesting that nonosmotic mechanisms are
involved.
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LOCAL MYOCARDIAL AND SYSTEMIC RENIN
ANGIOTENSIN SYSTEM
Noninfarcted regions of the myocardium appear to exhibit
activation of the tissue renin-angiotensin system with increased
angiotensin II production.  Both locally and systemically generated
angiotensin II can stimulate the production of various growth
factors, such as platelet-derived growth factor and transforming growth
factor, that promote compensatory hypertrophy in the noninfarcted
myocardium as well as control the structure and tone of the infarction
process include release of endothelin, PAI-1, and aldosterone, which
may cause vasoconstriction, impaired fibrinolysis, and increased socium
retention, respectively.  Inhibition of generation of circulating and tissue
angiotensin II is one of the proposed mechanisms of benefit from ACE
inhibitors in STEMI.
In patients with myocardial infarction, hyponatremia may
be aggravated further by the concomitant activation of the
renin-angiotensin system and increased catecholamine production 87,88.
These factors decrease the glomerular filtration rate and subsequent
delivery of tubular fluid to the diluting segment   of the nephron, further
contributing to decreased renal water    excretion 90.  Indeed, the degree
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of neurohormonal activation correlates with the severity of hyponatremia
in patients with chronic heart failure 89.
BNP levels may be a marker of the degree of left ventricular
dysfunction in patients with STEMI and that markedly elevated
levels of BNP correlate with a worse prognosis.91,92,93
ADRENAL CORTEX
Plasma and urinary 17-hydroxycorticosteroids and
ketosteroids, as well as aldosterone, are also markedly elevated in
patients with STEMI.  The magnitude of the elevation of cortisol
correlates with infarct size and mortality. Glucocorticosteroids also
contribute to the impairment of glucose tolerance13.
ECHOCARDIOGRAPHY AND PROGNOSIS AFTER AMI
The ease of use of Echocardiography, portability, and lack of
radiation or other biologic hazards make it an ideal investigation in
critically ill patients.  It enables estimation of cardiac function and wall
motion abnormalities.94
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Patients with normal ejection fraction (EF) by Echo have been
shown to have essentially no mortality or complications in hospital.  The
mortality was 2% with an EF >35% and 37% if <35%. A recent study
suggests that LV endsystolic volume may be an even more sensitive
index than the ejection fraction.94
Objective evaluation is also done by scoring the wall motion index
(normally = 1).  Peels et. al., have proven the prognostic value of the
wall motion score index (WMSI).  Kober et. al., found an association
between a WMSI of >1.6 and failure/death.95
Echo can also assess the area of dyskinesis, and show
expansion of infarcted area , thus predicting the prognosis.  It can also
show the success of reperfusion therapy as an increasing WMSI.  It can
be used to confirm the presence of complications that worsen the
outcome.  Doppler evaluation of mitral and peak aortic flow rates have
also been used for prognosis, and they have been found to correlate
well with pulmonary capillary wedge  pressure.96
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MATERIALS  AND  METHODS
This study was conducted in the Thanjavur Medical College
Hospital, Thanjavur, during the period of September, 2005 to March, 2006.
STUDY POPULATION
A total of 54 patients admitted to the Intensive Cardiac Care Unit
were studied.  There were 40 male and 14 female patients, ranging from
35 years to 85 years.  Average age of presentation  54.7 years.
CRITERIA FOR ENTRY INTO THE STUDY
Patients with a diagnosis of Acute Myocardial Infarction (AMI) were
entered into the study.  A definitive  diagnosis of AMI was made if the
patients satisfied the following criteria :-
i)A history of typical chest discomfort, lasting for more than
thirty minutes, not relieved by rest or nitrates.
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ii) Typical ECG changes of AMI (Q waves or ST/T wave changes
in two contiguous leads, or the appearance of new left bundle branch
block).
EXCLUSION CRITERIA
i) Patients with elevated renal parameters.
ii) Very late presentation more than 72 hours.
VARIABLES RECORDED AT ADMISSION
Routine history taking, physical examination and
laboratory investigations were performed in all subjects.  The
variables recorded specifically for the purposes of this study were as
follows :-
i) Presenting History :
- duration of chest discomfort
- associated symptoms
- time of onset of symptoms
- triggering factors, if any
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ii) Previous History :
- previous infarction or angina
- diabetes mellitus
- hypertension
- other cardiovascular diseases
- symptoms of cardiac failure
- use of tobacco and alcohol
- Contraindications to thrombolytic thereby
(recent surgery / trauma / bleeding /
cardiopulmonary resuscitation / CNS
diseases).
iii) Clinical Examination :
Special emphasis was placed on recording :-
- admission heart rate
- admission blood pressure
- signs of cardiac failure (including highest
level on the chest wall where crepitations
of cardiac failure, if any, are heard).
- signs of hypoperfusion
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iv) Admission Electrocardiogram (ECG) :
(a) Site of infarction :  anterior, inferior, lateral,
right ventricular, or combinations of these.
The sites were defined as follows : -
- Anterior :  Changes in VI to V4
- Inferior :  Changes in II, III, aVF
- Lateral :  Changes in V5, V6, I or aVL
- Right ventricular :  ST rise in V4R > V2
(b) Number of leads with
i.   Q waves and
ii.  ST elevation.
(v) Laboratory Investigation
- total WBC count
- blood sugar at the time of admission, 24, 48,
72 Hours
- Serum Sodium on admission, 24, 48,72 Hours
Levels were corrected at each time, point based on
the assumption that plasma sodium concentration
should fall by 1.6 mmol/L for every 100-mg/dL rise in
plasma glucose concentrations 100,101. Thus, for
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every 100mg/dL increase in plasma glucose
concentration above 100 mg/dL, 1.6 mmol/L was
added to the plasma sodium concentration.
- Serum Pottasium on admission, 24, 48,72 Hours
- Haemoglobin on admission,
- Blood Urea, Serum Creatinine
are measured.
Qualifying patients received thrombolytic therapy
with 1.5 million units of streptokinase, followed by heparin for    5 to 7 days.
Assessment of left ventricular ejection fraction by echocardiography
was performed either on day 4 or 5 of   hospitalization in most patients or
earlier if clinically indicated.
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DISCUSSION
A 54 patients in this study were all chosen with strict adherence to
the entry criteria. Most patients arrived at the hospital without prior
referrence by Doctor. Though some study have reported a difference in
mortality depending on the qualification of referring Doctor.Our
referred cases were too few in number to arrive such a conclusion.  30% of
patients are only referred by private practitioners.
In our study the overall mortality rate within 30 days is 12.9% Kerry
L.Lee., found that mortality rate within 30 days is 7% in his study, among
them 39% died within 24 hours.  Alexander Goldberg found 10% mortality
within 30 days following MI.
Many studies report the commonest location of MI is anterior
infarction, as in our study (27 out of 54 patients).  Mortality was also higher
in patients with anterior infarction compared to inferior infarction
(85.7% Vs. 14.3%).  Multiple  previous studies have reported that patients
with anterior infarction have the highest risk of death102.103,  and isolated
inferior infarction has been associated with the lowest risk.
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An increasing age has been found to worsen prognosis both in
terms of likelyhood of death and in the development of life threatening
complications 83 Age over 60 significantly increasing mortality  compared
to those less than 60 years.  The relation was relatively flat until age 60,
after which the risk of death accelerated dramatically.
In our study the percentage of mortality in males is more than
females.  Kerry L.Lee., found female sex was only a marginally
independent Prognostic factor (P=0.043) in his study49.
HYPONATREMIA
In our study hyponatremia was present in 10 out of 54 patients.   It
comes to 18.5%.  Comparing to Goldberg et. al., this is 5.6% higher than
what he found.  None of them presented with hyponatremia           receive
prior diuretic therapy.  Among hyponatremia on admission the mortality
rate is 30%.  Goldberg et. al., found 19.9% mortality in hyponatremic
patients on admission 97.
In a study of 235 patients admitted to a coronary care unit in the
prethrombolytic era (of whom 190 were subsequently diagnosed with acute
myocardial infarction), Flear et. al., found higher in-hospital
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mortality rates among patients with minimal plasma sodium levels
< 130 mmol/L 98.
Among the 44 patients who had normal sodium level on
admission, 12 developed hyponatremia during hospital course.  This
comes to 22.2% compared to 19.9% in the previous study.  Sodium level
was less than 130 mEq/litre in three patients (5.5%).
Two of them died with in 30 days in hyponatremia developing after
admissions.  This is 0.8% less than what Goldberg et. al., found in this
study 97.
THROMBOLYSIS AND HYPONATREMIA
In Hyponatremia on admission group 50% of them are thrombolysed
where as 41.6% only thrombolysed in hyponatremia  developed after
admission. Among  the 3 death in hyponatremia on admission group 2 are
thrombolysed.
SEX AND HYPONATREMIA
Among total 54 patients ,40 are males. The remaining 14 are
females.
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The 3 patients died in hyponatremia on admission group, all are
having anterior wall infarction.  Two of them showed persistently
hyponatremia in the course.  Kerry L.Lee., found high mortality rate in
anterior wall MI patients 49
Among the two patients who died in hyponatremia developed after
admission group, anterior and inferior wall MI shares 50%.  Those who
developed hyponatremia after admission only 41.6% of them
received diuretic therapy.
RISK FACTORS AND HYPONATREMIA
Hyponatremia is more common in diabetes mellitus, smoker and
alocohol patients.  Similar results found in the previous study.
Diabetes smoker alocholic patients are more prone to develop
hyponatremia after admission.
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KILLIP CLASSIFICATION AND HYPONATREMIA
Goldberg et. al., found higher killip classification are more prone to
develop hyponatremia97.  In our study hyponatremia on admission is more
common in Class I  and hyponatremia develped after admission is more
common in Class II.  This may be due to higher killip class (III, IV)  patients
makes only 9.2% in our study.  General prevalence of killip Class III, IV are
10 -15, 5 -10 respectively 99.
Kerry L.Lee., Eric J Topal found the prevalence of killip class - III, IV
is two persent in their study.  Even though few patients in killip
class III, IV their mortality rate was very high in their study.49
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Hyponatermia in STEMI
LVEF Diuretic
S.No. Name I.P.No. Age Sex Diagnosis Th Pre Adm 24 hr 48 hr 72 hr Adm 24 hr 48 hr 72 hr Adm 24 hr 48 hr 72 hr
1 Ramaiya 860591 45 M Ext. AWMI No DM 158 392 100 208 135 136 136 139 3.5 4.5 3.9 4.3 58% No
2 Ganapathy 860670 67 M AWMI No S+DM 228 228 184 212 139 136 131 131 4.6 40 4.3 3.9 49% Yes
3 Balaiyan 860945 60 M AS,IW MI No S+A 140 87 81 104 130 137 130 132 4.7 3.3 50 4.8 30% No
4 Nagarathinam 860952 85 M IW,PMI No HT 136 108 100 128 135 136 134 126 38 29 3.1 4.5 61% No
5 Franchis 861073 62 M IWMI No HT,DM 112 158 156 136 135 136 137 135 4.4 5.1 4.4 4.2 58% No
6 Ganathammal 861226 70 F ASMI No HT 96 128 134 164 132 138 131 134 3.8 3.9 4.1 4.3 50% No
7 Kannappan 861500 45 M ASMI Yes S+A 100 108 0 0 138 136 0 0 4.4 3.7 4.2 4.4 0 No
8 Thumbuswamy 861493 65 M ASMI No DM 124 140 105 136 138 130 137 132 4.6 4.4 3.9 4.2 62% Yes
9 Manikandan 861506 38 M Ext. AWMI No S 124 100 75 98 136 128 134 133 3.7 3.7 4 3.9 54% No
10 Dhatchinamoorthy 862000 45 M IWMI No DM 148 195 325 322 136 140 141 133 3.8 3.9 2.2 3.8 47% No
11 Mathivanan 862097 45 M AW,LATMI No S+A 123 115 46 80 136 134 138 133 3.9 3.7 3.6 3.7 68% No
12 Muniyamuthu 862125 64 M IW,PMI No DM,S 210 163 126 140 136 136 137 140 4.1 3.9 4.2 3.8 60% No
13 Shenbagavalli 862160 55 F ASMI No HT 86 106 108 118 135 139 136 140 4.1 4.3 3.5 3.8 54% No
14 Seethiammal 862367 60 F ASMI No HT 96 136 135 136 135 135 138 142 4 4.4 4.1 4.2 48% Yes
15 Jamil 862367 55 M IW,RVMI* Yes DM 217 132 108 170 138 139 138 138 4.2 4.1 4.1 3.9 38% No
16 Subramaniyan 862481 52 M IW,PMI Yes S+A 100 90 98 104 134 132 139 134 3.9 3.8 3.2 3.6 60% No
17 Sivagnannam 862105 50 M IWMI Yes HT 110 104 92 256 138 136 139 137 3.9 4.6 4.7 4.1 60% No
18 Murugaiyan 863589 55 M AWMI Yes DM,HT 101 92 102 96 135 127 136 136 3.9 4.7 4.8 4.2 51% Yes
19 Manikandan 863825 51 M IW,PMI Yes S+A 103 80 94 86 138 135 140 138 3.7 4.9 4.8 4.1 55% No
20 Kanagammal 864033 70 F IWMI Yes DM,HT 272 110 134 169 134 138 137 139 4.1 0.3 3.9 4.2 65% No
21 Murugaiyan 864392 50 M AWMI No DM 134 98 146 130 136 136 138 138 4.2 4.1 4.2 4.2 52% No
22 Palanivel 869847 50 M AWMI Yes S+A 84 90 106 98 132 133 140 134 4.1 3.9 4.5 5.1 54% No
23 Dharmalingam 869879 60 M IW,P,RVMI Yes HT 53 60 76 83 136 138 136 137 3.8 3.9 4.2 4.2 60% No
24 Pannerselvam 869892 38 M AWMI Yes S 120 110 98 116 130 132 136 132 4.3 3.8 3.2 3.6 58% No
25 Govindasamy 869964 68 M IW,PMI No DM 100 96 108 120 136 136 140 136 4.6 4.2 3.2 3.8 44% No
26 David 871035 62 M H.LATMI No HT 138 120 116 120 136 136 138 139 3.9 3.8 3.6 3.6 51% No
27 Govindaraj 871045 70 M GLOBALMI Yes HT 120 108 130 110 136 135 136 136 3.8 4.4 4.2 4.4 60% No
28 Rajagopal 871084 50 M IWMI Yes DM 180 114 136 148 135 138 142 141 4.3 4.2 4.2 4.3 50% No
29 Rajmohammed 871209 52 M IW,PMI Yes DM 164 140 180 165 135 135 136 138 4.5 4.2 4.3 4.2 60% No
30 Jayaraman 872795 68 M IW,PMI Yes HT,DM,S 576 209 228 180 136 131 132 136 3.9 4.6 4.4 4.4 67% Yes
31 Suresh 872902 35 M AWMI No S+A 68 57 96 86 135 132 136 133 3.7 3.8 3.9 3.9 55% Yes
32 Elamaran 872993 36 M IW,PMI Yes HT,S,A,DM 433 108 139 108 136 136 132 134 3.6 3 3.9 3.9 41% No
33 Pappa 872915 55 F AWMI Yes HT 94 98 106 80 139 138 138 139 4.4 3.8 4.1 3.8 64% No
34 Mangayarkarasi 872583 55 F PMI Yes DM 200 140 140 184 134 132 130 133 4.3 4.1 3.9 3 56% Yes
35 Elangovan 872451 52 M IWPMI Yes HT,S,A 77 90 108 86 137 138 140 136 4.2 4 4.1 4.1 65% No
36 Kannapillai 873749 55 M AWMI Yes DM 232 408 276 192 131 135 130 131 4.3 3.8 4.2 4.1 63% No
37 Rukhmani 875018 52 F IWPMI Yes HT 116 108 96 84 132 136 135 134 4.2 3.8 4.2 4.1 65% No
38 Meenammal 875261 55 F AWMI Yes HT,S 116 84 110 120 138 136 138 136 3.9 3.9 4 4.1 63% Yes
39 Jothi 875769 52 F AWMI No HT 120 96 110 98 139 136 141 144 4.3 4.2 4.1 4.2 60% No
40 Vedarathinam 876094 55 M AW,I, MI No S 79 110 98 76 136 135 136 139 3.9 3.8 4.2 4.2 36% No
41 Chandramohan 876389 50 M Ext. AWMI Yes HT 80 92 96 118 135 136 136 139 4.7 3.3 5 4.8 62% No
42 Raja 877244 32 M AWMI No DM,A 144 180 164 160 132 138 140 138 4 4.2 4.2 4.4 44% No
43 Sekar 877258 40 M IWMI Yes DM,S 140 128 96 138 138 136 136 136 4.3 4.2 4.1 4.3 65% No
44 Shahul Hameed 878850 62 M AWMI No HT,S 104 110 142 130 135 136 136 138 4.4 4.2 4.1 4.3 65% Yes
45 Lathika Beevi 878910 60 F IWMI Yes DM 208 148 160 170 136 131 132 132 3.3 3.6 3.2 3.2 61% No
46 Sivagami 878970 55 F IW,P,MI No HT 111 90 86 84 136 132 136 136 3.8 3.6 3.6 3.2 52% No
47 Arulanantham 881513 54 M IWMI No DM 124 140 184 164 138 136 138 136 3.4 4.5 4.3 4.2 60% No
48 Rajalakshmi 881552 50 F AWMI No HT,DM 363 320 280 262 133 136 134 133 4.1 4.2 4.4 4.2 50% No
49 Murugaiyan 881761 60 M IWMI YES HT,DM 82 110 122 121 131 136 132 132 4.4 4.2 4.2 4.6 50% No
50 Pattu 881793 70 F IWMI NO DM 92 110 140 118 132 132 132 130 3.7 3.6 3.6 3.8 46% No
51 selvam 881884 50 M PWMI Yes DM,S 236 240 242 218 140 134 136 138 4.1 4 3.8 3.6 50% No
52 Rajendran 881904 45 M AWMI NO HT 112 110 110 106 136 140 136 136 4.4 4.2 4.2 4 50% No
53 kaliyaperumal 882080 45 M H.LAT.MI YES S 119 120 122 136 136 140 138 138 3.7 3.6 3.2 3.2 46% No
54 Manickam 882125 76 M IWMI No HT 124 184 140 164 136 138 141 136 4.2 4.1 4.1 4 52% No
Blood Sugar Serum Sodium Serum Pottasiam
ABBREVIATIONS FOR MASTER CHART
Thy– thrombolysis,
Pre- previous history of DM, HT etc
DM-diabetes mellitus
HT-hypertension
S-smoker
A-alcohol habits
Adm- admission
AWMI -anterior wall myocardial infarction
ASMI –antero septel myocardial infarction
Ext,AWMI-extencive anterior wall myocardial infarction
IWMI- inferior wall myocardial infarction
P – posterior
RV-right ventricular infarction
N -no
Y-yes
Pulse –pulse rate / min
T.C.-total count
Hb.-haemoglobin
LVEF-left ventricular ejection fraction
A-alive
D-died
HYPONATREMIA IN ACUTE STEMI
NAME : Age: years. Sex: male/female
Occupation I.P.NO:
ADDRESS : D.O.A:
D.O.D:
Phone:
DATE & TIME OF ONSET OF PAIN:
DATE & TIME OF ADMISSION       :
SYMPTOMS: □ CHEST PAIN /□ DYSPNOEA /□SWEATING /□GIDDINESS
RISK FACTORS: DIABETES MELLITUS TYPE 1        TYPE 2 YEARS
HYPERTENSIVE                        YEARS
SMOKER YEARS
ALCOHOLIC YEARS
FAMILY HISTORY : DM/ HT/ CAHD
FINAL DIAGNOSIS :
KILLIP CLASSIFICATION: I  /  II  /   III  /  IV
□ THROMBOLYSED  /□ NOT THROMBOLYSED
DIURETIC THERAPY : □ YES /□NO
□ PREVIOUS / □STARTED
DAY ADMISSION DAY 2 DAY 3 DAY 4
Pulse  / min
B.P. mmHg
Basal Crepts
C.V.S.
INVESTIGATIONS:
URINE : BLOOD : Hb: T.C :
ALBUMIN: D.C:   P.      %  L.       %  E.     %
REDUCING SUBSTANCE : R.B.C:
BLOOD UREA :           mgs/dl                       SERUM CREATININE :         mgs/dl
ELECTRO CARDIO GRAPHIC FINDINGS :
DATE /DAY
RATE /MIN
RHYTHM
PR INTERAL
QRS COMPLEX
ST SEGMENT
T  WAVE
BLOCK
DAY ADMISSION 24 HOURS 48 HOURS 72 HOURS
Bl.sugar mgs%
Serum  Na
mEq/l
Corrected Na
mEq/l
Serum K mEq/l
ECHO CARDIO GRAPHIC FINDINGS :
CAHD- HYPOKINESIA OF  ANTERIOR WALL
LOWER ½  IVS
INFERIOR WALL
L V E F : %
OUTCOME  IN  30 DAYS : □ ALIVE
DEATH
